(Reuters) -The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Wegovy.
The health regulator reviewed Hims’ website in August and found the company was making false or misleading claims about its compounded semaglutide products, the active ingredient in Ozempic and Wegovy.
The warning comes just months after Novo Nordisk terminated its collaboration with Hims & Hers, citing illegal mass compounding and deceptive marketing practices.
Shares of Hims fell over 6% in afternoon trading.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Krishna Chandra Eluri)
Brought to you by www.srnnews.com
